Skip to content

Zhang Boyu Clinical Inheritance Research Base of Ding's School of Internal Medicine: Clinical observation on the therapeutic effect of Kanli granules on chronic heart failure

Zhang Boyu Clinical Inheritance Research Base of Ding's School of Internal Medicine

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084054
Enrollment
Unknown
Registered
2024-05-09
Start date
2014-09-26
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

experiment group:Kan Li granule
control group:conventional treatment

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) age 18-75 years old; (2) patients meet the diagnostic criteria of CHF (NYHA grade II-IV); (3) patients received a steady dose of conventional heart failure medications, including angiotensin converting enzyme inhibitors (ACEI), beta-blockers, oral diuretics, and aldosterone receptor antagonists, that had not changed for over 4 weeks before recruitment; (4) voluntarily participation and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) any study medicines or devices used within 4 weeks before recruitment; (2) known or suspected allergy or intolerance to study drugs or any conventional treatments in this trial; (3) current acute decompensated heart failure or aggravated poor conditions, with lower limbs dysfunction, which may need intravenous medication; (4) percutaneous coronary intervention or coronary artery bypass grafting or implantation of a pacemaker in the past 3months; (5) uncontrolled hypertension with systolic blood pressure (SBP) = 180 mmHg or diastolic blood pressure (DBP) = 100 mmHg, or severe arrhythmia; (6) serum creatinine > 2.5 times ULN, or serum bilirubin or AST or ALT > 2 times ULN at first visit; (7) history of malignant tumor within 5 years; (8) female participants who are pregnant, breast-feeding or have a positive pregnancy test; (9) any other reasons that the main researchers consider inappropriate for participation in the clinical trial that may affect the efficacy and/or safety evaluation of the study.

Design outcomes

Primary

MeasureTime frame
Heart function;

Secondary

MeasureTime frame
6MWD;quality of life;TCMSS;1-year rehospitalization;1-year mortality;withdraw rate of digoxin;withdraw rate of diuretics;

Countries

China

Contacts

Public ContactJiang Meixian

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

sylby2022@163.com+86 20256347

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026